Polymers for reversing heparin-based anticoagulation

• US 8,519,189 B2
• Filed: 09/27/2011
• Issued: 08/27/2013
• Est. Priority Date: 06/01/2011
• Status: Expired due to Fees

• Current Assignee: British Columbia Cancer Agency Branch (Province of British Columbia)
• Original Assignee: University of British Columbia
• Inventors: Kizhakkedathu, Jayachandran N., Shenoi, Rajesh A., Carter, Cedric J., Brooks, Donald E.
• Primary Examiner(s): Sullivan, Daniel
• Assistant Examiner(s): Cao, Ping
• Application Number:
  US13/504,841
• Publication Number:
  US 20130022647A1
• Time in Patent Office: 700 Days
• Field of Search: None
• US Class Current: 564/153
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 31/795 Polymers containing sulfur
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61M 1/3675 Deactivation
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0021 removed from and reintroduced into the body, e.g. after treatment
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/0478 Heparin
• CPC Class Codes: B01D 15/36 involving ionic interaction
• CPC Class Codes: C08G 2340/00 Filter material
• CPC Class Codes: C08G 73/024 Polyamines containing oxygen in the form of ether bonds in the main chain
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims

1. A heparin binding polymer, the polymer comprising:

a first dendritic polyol; and

one or more cationic moieties attached to the first dendritic polyol,

wherein the polymer comprises the structure of Formula (I);

3. The heparin binding polymer of claim 1, wherein at least the first dendritic polyol comprises a polyether polyol, and wherein the polymer is immobilized on a support.

4. The heparin binding polymer of claim 1, wherein the cationic moiety comprises Formula (VI):

5. The heparin binding polymer of claim 1, further comprising a protective moiety covalently attached to the first dendritic polyol.

6. The heparin binding polymer of claim 5, wherein the protective moiety comprises polyethylene glycol.

7. The heparin binding polymer of claim 6, wherein the polymer has a polyethelene glycol content of about 75% by weight.

8. The heparin binding polymer of claim 1, wherein the one or more cationic moieties comprises an amine group.

9. The heparin binding polymer of claim 8, wherein the amine group is a tetra-amine group, hexa-amine group, or a deca-amine group.

10. The heparin binding polymer of claim 8, wherein the amine group comprises a methylated amine.

11. The heparin binding polymer of claim 8, wherein the amine group comprises a methylated tetra-amine group, a methylated hexa-amine group, or a methylated deca-amine group.

12. The heparin binding polymer of claim 1, wherein the first dendritic polyol comprises a polyether polyol.

13. The heparin binding polymer of claim 12, wherein the polyether polyol is hyperbranched.

14. The heparin binding polymer of claim 12, wherein the polyether polyol has a degree of branching in the range of 0.05 to 0.95.

15. The heparin binding polymer of claim 14, wherein the degree of branching in the range of 0.40-0.65.

31. The heparin binding polymer of claim 1, wherein the heparin binding polymer binds to heparin selected from at least one of:

unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

32. The heparin binding polymer of claim 31, wherein the heparin binding polymer binds to fondaparinux.

2. A heparin binding polymer, the polymer comprising:

a first dendritic polyol; and

one or more cationic moities attached to the first dendritic polyol,

wherein the polymer comprises the structure of Formula (II);

16. The heparin binding polymer of claim 2, wherein at least the first dendritic polyol comprises a polyether polyol, and wherein the polymer is immobilized on a support.

17. The heparin binding polymer of claim 2, wherein the cationic moiety comprises Formula (VI):

18. The heparin binding polymer of claim 2, further comprising a protective moiety covalently attached to the first dendritic polyol.

19. The heparin binding polymer of claim 18, wherein the protective moiety comprises polyethylene glycol.

20. The heparin binding polymer of claim 19, wherein the polymer has a polyethelene glycol content of about 75% by weight.

21. The heparin binding polymer of claim 2, wherein the one or more cationic moieties comprises an amine group.

22. The heparin binding polymer of claim 21, wherein the amine group is a tetra-amine group, hexa-amine group, or a deca-amine group.

23. The heparin binding polymer of claim 21, wherein the amine group comprises a methylated amine.

24. The heparin binding polymer of claim 21, wherein the amine group comprises a methylated tetra-amine group, a methylated hexa-amine group, or a methylated deca-amine group.

25. The heparin binding polymer of claim 2, wherein the first dendritic polyol comprises a polyether polyol.

26. The heparin binding polymer of claim 25, wherein the polyether polyol is hyperbranched.

27. The heparin binding polymer of claim 25, wherein the polyether polyol has a degree of branching in the range of 0.05 to 0.95.

28. The heparin binding polymer of claim 27, wherein the degree of branching in the range of 0.40-0.65.

29. The heparin binding polymer of claim 2, wherein the heparin binding polymer binds to heparin selected from at least one of:

unfractionated heparin (UFH), low molecular weight heparin (LMWH), ultra low molecular weight heparin (ULMWH), fondaparinux, idraparinux enoxaparin, dalteparin, tinzaparin, semuloparin, or heparinoid.

30. The heparin binding polymer of claim 29, wherein the heparin binding polymer binds to fondaparinux.